MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032)[1].
[1]. Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1.
















